WO2005067969A3 - Kombinationen von serotonin-wiederaufnahme-hemmern und imidazolin-i2-agonisten - Google Patents

Kombinationen von serotonin-wiederaufnahme-hemmern und imidazolin-i2-agonisten Download PDF

Info

Publication number
WO2005067969A3
WO2005067969A3 PCT/EP2004/014284 EP2004014284W WO2005067969A3 WO 2005067969 A3 WO2005067969 A3 WO 2005067969A3 EP 2004014284 W EP2004014284 W EP 2004014284W WO 2005067969 A3 WO2005067969 A3 WO 2005067969A3
Authority
WO
WIPO (PCT)
Prior art keywords
imidazoline
agonists
combinations
serotonin reuptake
reuptake inhibitors
Prior art date
Application number
PCT/EP2004/014284
Other languages
English (en)
French (fr)
Other versions
WO2005067969A2 (de
Inventor
Gerd Bartoszyk
Amsterdam Christoph Van
Henning Boettcher
Christoph Seyfried
Original Assignee
Merck Patent Gmbh
Gerd Bartoszyk
Amsterdam Christoph Van
Henning Boettcher
Christoph Seyfried
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Gerd Bartoszyk, Amsterdam Christoph Van, Henning Boettcher, Christoph Seyfried filed Critical Merck Patent Gmbh
Priority to JP2006548147A priority Critical patent/JP4728257B2/ja
Priority to CA002553629A priority patent/CA2553629A1/en
Priority to AU2004313648A priority patent/AU2004313648B2/en
Priority to EP04803903A priority patent/EP1708754A2/de
Priority to US10/586,457 priority patent/US20080027140A1/en
Publication of WO2005067969A2 publication Critical patent/WO2005067969A2/de
Publication of WO2005067969A3 publication Critical patent/WO2005067969A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft Kombinationen von Serotonin-Wiederaufnahme-Hemmern und lmidazolin-l2-Agonisten als separate chemische Einheiten oder beide Eigenschaften vereint in einem Molekül sowie deren Verwendung zur Herstellung von Medikamenten zur Behandlung von Depression, Zwangsstörungen (obsessive compulsive disorders, OCD), Zwangsspektrums-Störungen (OCSD) und anderen Angstzuständen.
PCT/EP2004/014284 2004-01-19 2004-12-15 Kombinationen von serotonin-wiederaufnahme-hemmern und imidazolin-i2-agonisten WO2005067969A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006548147A JP4728257B2 (ja) 2004-01-19 2004-12-15 セロトニン再取込み阻害薬およびイミダゾリンｉ２作動薬の組み合わせ
CA002553629A CA2553629A1 (en) 2004-01-19 2004-12-15 Combinations of serotonin reuptake inhibitors and imidazoline-i2-agonists
AU2004313648A AU2004313648B2 (en) 2004-01-19 2004-12-15 Combinations of serotonin reuptake inhibitors and imidazoline-I2-agonists
EP04803903A EP1708754A2 (de) 2004-01-19 2004-12-15 KOMBINATIONEN VON SEROTONIN-WIEDERAUFNAHME-HEMMERN UND IMIDAZOLIN-I sb 2 /sb -AGONISTEN
US10/586,457 US20080027140A1 (en) 2004-01-19 2004-12-15 Combinations of Serotonin Reuptake Inhibitors and Imidazoline I 2 Agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004002638A DE102004002638A1 (de) 2004-01-19 2004-01-19 Kombinationen von Serotonin-Wiederaufnahme-Hemmern und Imidazolin-I2-Agonisten
DE102004002638.6 2004-01-19

Publications (2)

Publication Number Publication Date
WO2005067969A2 WO2005067969A2 (de) 2005-07-28
WO2005067969A3 true WO2005067969A3 (de) 2007-04-05

Family

ID=34778082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/014284 WO2005067969A2 (de) 2004-01-19 2004-12-15 Kombinationen von serotonin-wiederaufnahme-hemmern und imidazolin-i2-agonisten

Country Status (7)

Country Link
US (1) US20080027140A1 (de)
EP (1) EP1708754A2 (de)
JP (1) JP4728257B2 (de)
AU (1) AU2004313648B2 (de)
CA (1) CA2553629A1 (de)
DE (1) DE102004002638A1 (de)
WO (1) WO2005067969A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1846430T1 (sl) 2005-02-09 2009-08-31 Basilea Pharmaceutica Ag Novi makrolidi
US20100298305A1 (en) * 2008-11-26 2010-11-25 The United States Government, As Represented By The Department Of Veterans Affairs Tizanidine for the treatment of post-traumatic stress disorder and nightmares

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919234A2 (de) * 1997-10-17 1999-06-02 Eli Lilly And Company Potenzierung von Wirkstoffen durch Moxonidine
WO2000002878A1 (en) * 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
WO2003075914A1 (en) * 2002-03-14 2003-09-18 EGIS Gyógyszergyár Rt. Citalopram for the treatment of elevated blood pressure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914235A (en) * 1996-10-11 1999-06-22 Eli Lilly And Company Potentiation of 3 H! 2-(2-benzofuranyl)-2-imidazoline (BFI) binding sites in human tissue by tranylcypromine (TCP)
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0919234A2 (de) * 1997-10-17 1999-06-02 Eli Lilly And Company Potenzierung von Wirkstoffen durch Moxonidine
WO2000002878A1 (en) * 1998-07-11 2000-01-20 University Of Bristol Compounds having activity at imidazoline receptors
WO2003075914A1 (en) * 2002-03-14 2003-09-18 EGIS Gyógyszergyár Rt. Citalopram for the treatment of elevated blood pressure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU A ET AL: "Imidazoline receptor agonist drugs: A new approach to the treatment of systemic hypertension", JOURNAL OF CLINICAL PHARMACOLOGY 1996 UNITED STATES, vol. 36, no. 2, 1996, pages 98 - 111, XP000892878, ISSN: 0091-2700 *

Also Published As

Publication number Publication date
EP1708754A2 (de) 2006-10-11
JP4728257B2 (ja) 2011-07-20
AU2004313648A1 (en) 2005-07-28
WO2005067969A2 (de) 2005-07-28
DE102004002638A1 (de) 2005-08-18
CA2553629A1 (en) 2005-07-28
AU2004313648B2 (en) 2010-09-30
US20080027140A1 (en) 2008-01-31
JP2007520475A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
TW200640529A (en) Composition for treating mental health disorders
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2006124748A3 (en) Multicyclic compounds and methods of their use
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2008046007A3 (en) A process for preparing aluminum-containing molecular sieve ssz-26
WO2007045462A3 (de) Neue vanilloid-rezeptor liganden und ihre verwendung zur herstellung von arzneimitteln
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
WO2007106721A3 (en) Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
EP2009084A4 (de) Schmierstoffgrundöl, herstellungsverfahren dafür und schmierölzusammensetzung
EP1494673A4 (de) Verbindungen mit einzigartiger cb1-rezeptor-bindungsselektivität und herstellungs- und anwendungsverfahren dafür
WO2007084841A3 (en) Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
WO2007081542A3 (en) Tetralone-based monoamine reuptake inhibitors
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2007131219A3 (en) Cannabinoid receptor antagonists/inverse agonists
WO2008076324A3 (en) Compositions and methods to treat muscular & cardiovascular disorders
WO2007028132A3 (en) 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
WO2009092052A3 (en) Methods and compositions for treating polyps
WO2007035872A3 (en) Tdf-related compounds and analogs thereof
WO2008065282A3 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
ATE384046T1 (de) Verfahren zur asymmetrischen hydrierung, das sich für die herstellung von cycloalkanindolderivaten eignet
WO2007111982A3 (en) Methods for treating cognitive and other disorders
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004803903

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2553629

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10586457

Country of ref document: US

Ref document number: 2006548147

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004313648

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004313648

Country of ref document: AU

Date of ref document: 20041215

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004313648

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004803903

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10586457

Country of ref document: US